Lamberts S W, Oosterom R
J Clin Endocrinol Metab. 1983 Feb;56(2):230-3. doi: 10.1210/jcem-56-2-230.
The effect of the infusion of 2-hydroxyestrone (125 micrograms/h for 8 h) on plasma PRL levels was investigated before and 64 h after the administration of 1 mg estradiol benzoate in five patients with PRL-secreting pituitary adenomas. There was no effect on the circulating PRL levels measured hourly for 8 h during both episodes of 2-hydroxyestrone infusion, but plasma LH and FSH levels were suppressed. Infusion of 2-hydroxyestrone in two hyperprolactinemic patients with craniopharyngeomas also did not change the circulating PRL levels. We conclude that: 1) 2-Hydroxyestrone does not suppress PRL levels in patients with prolactinomas. This is not caused by the low estrogenic state of these patients, because 2-hydroxyestrone remained ineffective after the administration of estradiol. 2-Hydroxyestrone was also not able to suppress the estradiol-induced stimulation of PRL release. 2) 2-Hydroxyestrone does not diminish PRL levels in patients with suprasellar tumors and hyperprolactinemia. Therefore, infusion of 2-hydroxyestrone cannot be used in the differential diagnosis of hypothalamic and tumoral hyperprolactinemia.
在5例分泌泌乳素的垂体腺瘤患者中，研究了静脉输注2-羟雌酮（125微克/小时，共8小时）对血浆泌乳素水平的影响，观察时间为给予1毫克苯甲酸雌二醇前及给药后64小时。在两次2-羟雌酮输注期间，连续8小时每小时测量的循环泌乳素水平均未受影响，但血浆促黄体生成素（LH）和促卵泡生成素（FSH）水平受到抑制。在两名患有颅咽管瘤的高泌乳素血症患者中输注2-羟雌酮，也未改变循环中的泌乳素水平。我们得出以下结论：1）2-羟雌酮不会抑制泌乳素瘤患者的泌乳素水平。这并非由这些患者的低雌激素状态所致，因为给予雌二醇后2-羟雌酮仍然无效。2-羟雌酮也无法抑制雌二醇诱导的泌乳素释放刺激。2）2-羟雌酮不会降低鞍上肿瘤伴高泌乳素血症患者的泌乳素水平。因此，输注2-羟雌酮不能用于下丘脑性和肿瘤性高泌乳素血症的鉴别诊断。
